Atara Biotherapeutics to present ‘positive’ tab-cel data during ESMO session

Atara Biotherapeutics announced positive new data for tabelecleucel in patients with relapsed or refractory or treatment-naive Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving the central nervous system following solid organ transplant or hematopoietic cell transplant. These results will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology Annual Congress taking place December 6-8, 2023, in Geneva, Switzerland. The clinical experience from this combined analysis of four single-arm, open-label studies, including the multicohort Phase 2 EBVision trial expands on previous data from two single-center, Phase 2 studies, and multicenter, expanded-access protocol. “EBV+ CNS PTLD is a rare but extremely serious disease, and patients often face a poor prognosis that underscores the urgent medical need,” said AJ Joshi, M.D., Executive Vice President, Chief Medical Officer at Atara. “We’re pleased to share new multicenter data, including the first results from our ongoing multicohort EBVision trial and first clinical trial report of treatment with tab-cel in the first line setting. Tab-cel shows a strong objective response rate in these high-risk patients with a favorable safety profile for patients with EBV-driven diseases.”